Preferential utilization of NADPH as the endogenous electron donor for NAD(P)H:quinone oxidoreductase 1 (NQO1) in intact pulmonary arterial endothelial cells by Bongard, Robert D et al.
Marquette University
e-Publications@Marquette
Mathematics, Statistics and Computer Science
Faculty Research and Publications
Mathematics, Statistics and Computer Science,
Department of
1-1-2009
Preferential utilization of NADPH as the
endogenous electron donor for
NAD(P)H:quinone oxidoreductase 1 (NQO1) in
intact pulmonary arterial endothelial cells
Robert D. Bongard
Medical College of Wisconsin
Brian J. Lindemer
Medical College of Wisconsin
Gary S. Krenz
Marquette University, gary.krenz@marquette.edu
Marilyn P. Merker
Medical College of Wisconsin
Accepted version. Free Radical Biology and Medicine, Vol. 46, No. 1, ( January, 2009): 25-32. DOI. ©
2009 Elsevier. Used with permission.
Preferential utilization of NADPH as the endogenous electron
donor for NAD(P)H:quinone oxidoreductase 1 (NQO1) in intact
pulmonary arterial endothelial cells
Robert D. Bongard1, Brian J. Lindemer2, Gary S. Krenz3, and Marilyn P. Merker2,4,5
3 Department of Mathematics, Statistics and Computer Sciences, Marquette University, Milwaukee, WI
2 Department of Anesthesiology, Medical College of Wisconsin
4 Department of Pharmacology and Toxicology, Medical College of Wisconsin
1 Department of Pulmonary Medicine, Medical College of Wisconsin
5 Zablocki VA Medical Center, Milwaukee, WI 53295
Abstract
The goal was to determine whether endogenous cytosolic NAD(P)H:quinone oxidoreductase 1
(NQO1) preferentially utilizes NADPH or NADH in intact pulmonary arterial endothelial cells in
culture. The approach was to manipulate the redox status of the NADH/NAD+ and NADPH/
NADP+ redox pairs in the cytosolic compartment using treatment conditions targeting glycolysis and
the pentose phosphate pathway alone or with lactate, and to evaluate the impact on the intact cell
NQO1 activity. Cells were treated with 2-deoxyglucose (2-DG), iodoacetate (IOA) or
epiandrosterone (EPI) in the absence or presence of lactate, NQO1 activity was measured in intact
cells using duroquinone (DQ) as the electron acceptor and pyridine nucleotide redox status was
measured in total cell KOH extracts by high performance liquid chromatography (HPLC). 2-DG
decreased the NADH/NAD+ and NADPH/NADP+ ratios, by 59% and 50%, respectively, and intact
cell NQO1 activity by 74%; lactate restored NADH/NAD+, but not NADPH/NADP+ or NQO1
activity. IOA decreased NADH/NAD+ but had no detectable effect on NADPH/NADP+ or NQO1
activity. EPI decreased NQO1 activity by 67%, and while EPI alone did not alter NADPH/NADP+
or NADH/NAD+, when the NQO1 electron acceptor DQ was also present, NADPH/NADP+
decreased by 84% with no impact on NADH/NAD+. DQ alone also decreased NADPH/NADP+ but
not NADH/NAD+. The results suggest that NQO1 activity is more tightly coupled with the redox
status of the NADPH/NADP+ than NADH/NAD+ redox pair, and that NADPH is the endogenous
NQO1 electron donor. Parallel studies of pulmonary endothelial transplasma membrane electron
transport (TPMET), another redox process that draws reducing equivalents from the cytosol,
confirmed previous observations of a correlation with the NADH/NAD+ ratio.
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Introduction
NAD(P)H:quinone oxidoreductase (NQO1) is a predominately cytosolic (>90%) two-electron
quinone reductase ubiquitously distributed in a wide range of tissue and cell types including
the pulmonary endothelium and other lung cell types [1–11]. NQO1 catalyzes reduction of a
broad range of physiological, pharmacological and toxicological quinones and other redox
active substances, wherein it may promote either protective or toxic effects, depending on the
chemical properties of the substrate and product formed [2,7,11]. NQO1 has been implicated
in protection from carcinogenesis, superoxide scavenging, modulation of intracellular redox
status, cellular metabolism and cancer cell growth, signaling mediated by tumor necrosis factor
and other inflammatory mediators, regeneration of antioxidants and other processes [6,7,12–
19].
Given its role in protection and activation of quinones and other redox active compounds, the
relatively high NQO1 expression in endothelium and epithelium is perhaps not surprising given
that they represent cell types in direct contact with airborne or blood-borne xenobiotics [10].
In this regard, the pulmonary endothelium is of particular importance because of its large
surface area and position in the circulation. These characteristics confer on pulmonary
endothelial and other lung cell enzymes the ability to influence the chemical composition of
the plasma, including the redox status and disposition of redox active compounds, during
passage of the blood from the venous to the systemic arterial circulations [5,20–23]. For
example, when duroquinone (DQ) is introduced into the pulmonary arterial inflow of the
perfused rodent lung, or into the extracellular medium of pulmonary arterial endothelial cells
in culture, durohydroquinone (DQH2) is generated in the perfusate and extracellular medium,
respectively, with the effect in this case attributable predominately to NQO1 [4,5,9,24]. The
implication is that pulmonary endothelial NQO1 provides a means for altering the bioactivity
of cell membrane permeant NQO1 substrates not only within the lung, but also within the blood
and downstream vessels and organs. Another NQO1 function with potential particular
significance to the pulmonary endothelium, given its high sensitivity to oxidative stress, is its
superoxide scavenging activity [6,12].
Despite the attention that has been focused on identification of NQO1 substrates and products
in various cells and tissues, and the fact that it is well known that isolated NQO1 oxidizes
NADH and NADPH virtually indiscriminately, the question of NQO1 electron donor
specificity, if any, within intact cells and tissues has not been investigated [1,3]. The importance
of identifying the donor relates to the capacity of the pulmonary endothelium to regenerate the
required donor in oxidative stress or other pathophysiological conditions in which there may
be a high competing demand for NAD(P)H and/or NAD(P)+ to sustain both NQO1 activity
and that of other protective mechanisms, e.g., NADPH for glutathione reductase or NAD+ for
poly-ADP ribose polymerase (PARP).
Therefore, the objective of the present study was to evaluate whether an electron donor
preference for NQO1 activity could be observed in intact pulmonary arterial endothelial cells,
and if so, whether NADH or NADPH could be identified as the donor. To address this question,
we manipulated cellular pyridine nucleotide redox status of pulmonary arterial endothelial cells
using metabolic inhibitors and treatment conditions directed at glycolysis and the pentose
phosphate pathway. We also targeted pyridine nucleotide redox status using lactate, which
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represents a physiological modulator of the cell redox environment. Intracellular NADH,
NAD+, NADPH and NADP+ were quantified by KOH extraction of the cells followed by high
performance liquid chromatography (HPLC), and intact cell NQO1 activity was measured
using DQ as the electron acceptor, as we have previously described [4,24]. Parallel studies
were carried out with the TPMET thiazine electron acceptor, toluidine blue O polymer (TBOP),
to provide a basis of comparison with an established NADH dependent redox process, and to
extend our previous observations of this pulmonary endothelial redox function [21,23,25,26].
Materials and Methods
Materials
Potassium hexacyanoferrate (III) (hereafter referred to as  or ferricyanide), 2,3,5,6-
tetramethyl-1,4-benzoquinone (duroquinone, hereafter referred to as DQ), 2-deoxyglucose (2-
DG), iodoacetic acid sodium salt (IOA), epiandrosterone (EPI), N-2-hydroxyethylpiperazine-
N′-2-ethanesulfonic acid (HEPES), dicumarol, L-(+)-lactic acid sodium salt (lactate), ATP and
other chemicals unless otherwise noted were purchased from Sigma Chemical (St. Louis, MO).
Trypsin, penicillin-streptomycin and RPMI 1640 tissue culture medium and fetal calf serum
were from Invitrogen (Grand Island, NY). Biosilon beads were from Nunc (Roskilde,
Denmark). NAD+, NADP+, NADPH and NADH standards for HPLC were purchased from
Boehringer Mannheim (Indianapolis, IN). The NQO1 inhibitor ES936 was the kind gift of
Dr.’s David Siegel and David Roth (School of Pharmacy, University of Colorado Health
Sciences Center, Denver, CO).
Endothelial cell culture
Bovine pulmonary arterial endothelial cells were isolated from segments of calf pulmonary
artery obtained from a local slaughterhouse, and cells between passages 4 and 20 were cultured
to confluence on Biosilon microcarrier beads (mean diameter 230 μm; surface area 255 cm2/
gm beads) in magnetic stirrer bottles (Techne Inc., Burlington, N.J.) containing RPMI 1640
medium supplemented with 20% fetal calf serum, 100 U/ml penicillin, 100 μg/ml streptomycin
and 30 mg/ml L-glutamine as previously described [26]. The cells were 99.5% positive for
DiO-acetylated-low density lipoprotein (Biomedical Technologies) uptake as measured by
fluorescence activated cell sorting and exhibited cobblestone morphology as observed by phase
contrast microscopy.
Treatment Conditions
Approximately 0.3 - 0.2 ml packed volume of cell coated beads were aliquoted from the stirred
culture flasks into spectrophotometric cuvettes or conical-bottomed centrifuge tubes. After the
cell coated beads had settled, they were washed three consecutive times by resuspension in 3
ml of Hank’s Balanced Salt Solution (HBSS) containing 10 mM HEPES, pH 7.4 (HBSS/
HEPES), allowing the beads to settle between each wash. The cell coated beads were
resuspended in 3 ml of HBSS/HEPES only (control) or HBSS/HEPES containing the inhibitor
or lactate treatments. Except when specified the HBSS/HEPES contained 5.5 mM glucose. For
the spectrophotometric studies, the treatment conditions were as follows: 5 mM lactate; 10 mM
2-DG in glucose-free buffer; 10 mM 2-DG and 5 mM lactate in glucose-free buffer; 0.4 mM
IOA; 0.4 mM IOA and 5 mM lactate; 0.03 mM EPI; 0.03 mM EPI and 5 mM lactate; 10 μM
dicumarol or 0.05 μM ES936. For the HPLC studies, the treatments were as follows: 5 mM
lactate; 10 mM 2-DG in glucose-free buffer; 10 mM 2-DG and 5 mM lactate in glucose-free
buffer; 0.4 mM IOA; 0.4 mM IOA and 5 mM lactate; 0.03 mM EPI; 0.03 mM EPI and 5 mM
lactate; 0.05 mM DQ; 0.05 mM DQ and 0.03 mM EPI. The cells were incubated in the treatment
media by mixing on a Nutator mixer at 37°C for 10 min before measurements of NQO1 and
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TPMET activities or pyridine nucleotide and ATP concentrations. After the 10 min mixing
period the buffer was removed from the cuvettes and saved for measurement of LDH activity.
Toluidine blue-O polymer
To prepare the toluidine blue-O polymer (TBOP), toluidine blue-O was incorporated in an
acrylamide polymer by copolymerization of toluidine blue-O-methylacrylamide and
acrylamide as previously described [23]. Polymer chains of less than 3.5KDa were removed
by dialysis through a 3.5 KDa cutoff membrane. The amount of reducible TBO+ per unit mass
of the TBO polymer (TBOP+) was approximately 17 nmoles/mg [25].
Protocol for measuring TPMET and NQO1 activity in intact cells
DQ or TBOP+ mediated reduction of the cell membrane impermeant secondary electron
acceptor, ferricyanide, were used as measures of NQO1 and TPMET activities, respectively,
as previously described [4,23–25]. Following the 10-min treatment period described in
Treatment Conditions, the cell coated beads were resuspended in 3 ml of fresh HBSS/HEPES
containing 600 μM ferricyanide in the absence or presence of DQ (50 μM) or TBOP (0.2 mg/
ml) with the same treatments to which the cells were exposed during the previous 10-min
treatment incubations. The suspensions were mixed on a Nutator mixer at 37°C, and
periodically the mixing was stopped, the cell coated beads allowed to settle at the bottom of
the spectrophotometric cuvettes out of the spectrophotometer light path, and the absorbance
of ferricyanide in the medium measured at 421 nm using a Beckman Model DU 7400
spectrophotometer.
The amount of the ferricyanide reduction product, ferrocyanide ( ) in each sample
was calculated from the decrease in ferricyanide absorbance at each time point (extinction
coefficient = 1.0 mM−1·cm−1). DQ or TBOP+ mediated ferricyanide reduction rates were
determined from linear regression fits of the individual ferricyanide versus time curves [4,23,
24]. The background rates of cell mediated ferricyanide reduction in the absence of DQ or
TBOP were subtracted from the individual rates obtained in their presence, normalized to the
cell protein, and then combined to obtain mean rates. The DQ or TBOP+ reduction rates were
calculated as one-half the zero order ferricyanide reduction rates in the presence of the electron
acceptors. The underlying assumptions are that DQ and durohydroquinone (DQH2) are freely
permeable to intracellular sites of reduction and oxidation, respectively, whereas TBOP+ is
reduced at the cell surface via transplasma membrane electron transport (TPMET) [4,23,24].
In addition, ferricyanide reduction by DQH2, and the reduced form of TBOP+, TBOPH, is
virtually instantaneous on the time course of the experiments, such that ferricyanide acts as a
sink for the DQH2 or TBOPH generated by the cells [4,23,24]. This approach is assumed to
minimize the confounding contribution of cell mediated DQH2 or TBOPH oxidation to the
measurement, thereby allowing for an estimate of reduction rate.
HPLC measurements of intracellular pyridine nucleotides and ATP
Following the 10 min treatments described in Treatment Conditions above, the cell coated
beads were allowed to settle and the experimental medium was removed. The details of the
KOH extraction procedure and the HPLC separation method have been previously described
[25]. The only difference for the present study was the HPLC equipment and software, which
was composed of a binary pump (Beckman model 126 solvent module), autosampler (Beckman
model 508), diode array detector (Beckman Coulochem II), a helium degasser for the mobile
phase and Beckman 32 Karat chromatography software. Quantification was by peak area
against standard curves generated by subjecting the standards to the same extraction treatment
as the cells. The standard curves for all pyridine nucleotides and ATP were linear in the
concentration range measured in the cell extracts. At the end of each experiment, the
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microcarrier beads were dried and weighed to determine the cell culture surface area, providing
a means for normalizing data between experiments.
NQO1 and glucose-6-phosphate dehydrogenase (G-6-PDH) activities in cytosol fractions
Cytosol-enriched fractions from untreated cells were obtained by sonication (3 pulses of 15
sec each with the power output set to 6 watts using a Microson Ultasonic Cell Disrupter,
Farmington, NY) of ~ 0.2 ml of packed cell-coated beads on ice in 1 ml of 2 mM HEPES
buffer, pH 7.4. The lysates were centrifuged for 30 min at 10,000 × g at 4°C to obtain a cytosol-
enriched fraction.
NQO1 activity was determined by measuring the reduction rate of 2,6-
dichlorophenolindophenol (DCPIP; 50 μM) spectrophotometrically at 600 nm (extinction
coeffiecient 21.0 mM−1·cm−1) following the addition of cell cytosol fraction (~10 μg protein)
to a reaction mixture containing 25 mM Tris-HCl, 0.02% bovine serum albumin, 0.01% Tween
20, 5 μM flavin adenine nucleotide (FAD) and 200 μM NADPH, pH 7.4, as had been previously
described [4]. The difference between the reaction rates in the absence and presence of 10 μM
dicumarol was used to calculate the NQO1 activity. G-6-PDH activity was determined by
measuring the rate of NADPH generation from NADP+ spectrophotometrically at 340 nm
(extinction coefficient 6.22 mM−1·cm−1) at 25°C following the addition of cytosol-enriched
fraction (~75 μg protein) to a reaction mixture containing 55mM Tris-HCl (pH 7.4), 3.3 mM
MgCl2·6H2O, 3.3 mM glucose-6-phosphate (G-6-P) or 3.3 mM 2-deoxyglucose-6-phosphate
(2-DG-6-P) and 2.0 mM NADP+ [27]. NQO1 and G-6-PDH activities in cytosol-enriched
fractions were also determined in the presence of 0.1 mM and 0.03 mM EPI, respectively. The
reaction rates were normalized to the protein content of the cytosol-enriched fractions as
measured by the Bio-Rad protein assay.
Additional measurements
Lactate dehydrogenase (LDH) activity in the treatment medium and in the cells at the end of
each experimental protocol for the spectrophotometric studies was determined as previously
described [26]. The extracellular medium was removed from the cells, the cells were sonicated
on ice, and LDH activity in the extracellular medium and the cell lysate was measured. The
fraction of the total cell LDH released into the cell medium for all studies combined was 2.0
± 0.1 and 2.5 ± 0.1% (mean ± SEM) during the 10-min treatment and the 30-min DQ- and
TBOP+-ferricyanide reaction periods, respectively. For all experiments for control and treated
cells (n = 198), no significant differences in LDH release between control and the treatment
conditions (Kruskal-Wallis one way ANOVA based on ranks, (p > 0.05) were detected.
To normalize the data for comparisons between studies, the protein content of the cells in each
experiment was measured using the BioRad protein reagent as previously described [26].
NQO1 and TPMET activities are expressed as nmol of DQ or TBOP+ reduction per min per
mg protein (nmol·min−1·mg−1 protein). Pyridine nucleotide and ATP concentrations are
expressed as pmol per cm2 cell surface area. One cm2 of cell surface area for endothelial cells
cultured on the Biosilon microcarrier beads is equivalent to 29.4 ± 0.5 μg (mean ± SE) protein,
~1.7 mg of DNA and ~128,000 cells [25].
Statistical Analysis
Results are expressed as mean ± standard error (mean ± SEM). Statistical analysis was
performed using SigmaStat (Jandel Scientific, San Rafael, CA). Differences between groups
were evaluated using the unpaired t-test, one-way analysis of variance (one way ANOVA)
followed by the Tukey post hoc test or when appropriate, the Kruskal-Wallis one-way ANOVA
on Ranks followed by Dunn’s post hoc test. Statistical significance was assumed at p < 0.05.
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Results
Figure 1 illustrates the approach used to measure NQO1 and TPMET activities in the intact
pulmonary arterial endothelial cells. The cell membrane impermeant secondary redox
indicator, ferricyanide, was added to the medium surrounding the cells in the presence of DQ
to measure NQO1 (Figure 1A) or TBOP+ to measure TPMET (Figure 1C) activity. Also
included were controls in which ferricyanide only was added to the medium surrounding the
cells (Figures 1A and 1C). There was little detectable reduction of ferricyanide to its ferro form
when ferricyanide only was present, indicating that the ferricyanide reduction observed in the
presence of DQ or TBOP is secondary to cell mediated generation of durohydroquinone
(DQH2) or the reduced form of TBOP+, TBOPH, respectively (Figures 1A and 1C), as we have
previously described [4,23,24]. Under these reaction conditions, DQ and TBOP+ are
continually regenerated and ferricyanide reduction remains zero order until the ferricyanide is
exhausted, as expected of a secondary electron acceptor that is essentially irreversibly reduced
and does not influence the primary reduction rate.
Figures 1A and 1B also show that dicumarol, a competitive NQO1 inhibitor, and ES936, an
irreversible NQO1 inhibitor, largely blocked DQ reduction, consistent with previous
observations that DQ acts as predominately as an NQO1 electron acceptor in intact pulmonary
arterial endothelial cells [4,19,24]. In contrast to its effects on DQ reduction, dicumarol had
no appreciable effect on TBOP+ reduction (Figures 1C and 1D). Together with the fact that,
because of its size, TBOP is unable to enter cells in the oxidized or reduced form, these
observations emphasize the utility of cell mediated DQ and TBOP+ mediated ferricyanide
reduction rates for non-destructive measurement of NQO1 and TPMET activities, respectively,
in intact pulmonary endothelial cells [23].
Figures 2A and B show the effects of the treatment conditions on NQO1 and TPMET activities,
respectively. 2-DG inhibited both NQO1 and TPMET activities whereas IOA preferentially
inhibited TPMET, and EPI preferentially inhibited NQO1.
Figures 3A and B show the effects of the treatment conditions on the total KOH extractable
cellular NADPH/NADP+ and NADH/NAD+ ratios. 2-DG decreased both the NADPH/
NADP+ and the NADH/NAD+ ratios (Figures 3A and B) and IOA depressed the NADH/
NAD+ but not the NADPH/NADP+ ratio (Figures 3A and B). EPI by itself did not affect the
redox status of either pyridine nucleotide pair (Figures 3A and B), which was somewhat
unexpected due to the marked effect of EPI on NQO1 activity (Figure 2A). However, the effect
of DQ itself to depress the NADPH/NADP+ ratio was more pronounced in the presence of EPI
(DQ + EPI) (Figure 3A). Notably, the effects of DQ without or with EPI were specific to the
NADPH/NADP+ redox pair since there was no corresponding decrease in the NADH/NAD+
ratio in either condition (Figure 3B).
The data in Figures 2 and 3 suggested that NQO1 activity was reflective of the cytosolic
NADPH/NADP+ redox status, whereas TPMET was more highly associated with the cytosolic
NADH/NAD+ ratios, the latter being consistent with previous studies [25]. If this were indeed
the case, we would predict that treatment of the cells with lactate, which is reduced to NADH
via lactate dehydrogenase, would overcome the effects of 2-DG and IOA on pulmonary
endothelial NADH/NAD+ redox status and TPMET activity, as observed in previous studies
[25], but not the effects of 2-DG or EPI on NADPH/NADP+ redox status or the NQO1 activity.
As seen in Figures 4A and B, the addition of lactate to the 2-DG or IOA treatments overcame
the inhibitor effects on both NADH/NAD+ redox status and TBOP+ reduction rate (i.e. TPMET
activity). However, lactate could not overcome the effect of 2-DG on the DQ reduction rate
(i.e., NQO1 activity), and the NADPH/NADP+ ratio was not significantly different in the
presence of 2-DG or 2-DG + lactate (Figures 5B and A, respectively).
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The oxidized and reduced pyridine nucleotide concentrations used to calculate the NAD(P)H/
NAD(P)+ ratios in Figures 3–5, along with the ATP concentrations for each treatment condition
are shown in Table 1.
Figure 6A and B show that EPI had the intended effect insofar as it inhibited G-6-PDH but not
NQO1 activity as measured in cell cytosol fractions. Also shown in Figure 6B is that G-6-PDH
activity in cell cytosol fractions was much lower when the substrate was 2-DG-6-P, the product
of hexokinase catalyzed 2-DG phosphorylation, than with the physiological substrate, G-6-P
(control). To emphasize this point, Figure 6B shows that 2-DG-6-P synergizes with EPI to
inhibit G-6-PDH.
Discussion
The goal of the present study was to determine whether endogenous NQO1, which is
predominately (>90%) located in the cell cytosol, exhibits a propensity for preferential
oxidation of NADH or NADPH in intact pulmonary endothelial cells. The general strategy was
to manipulate cytosolic redox status using treatment conditions directed at the glycolytic and
pentose phosphate pathway, and lactate, and to evaluate the effects on pyridine nucleotide
redox status and NQO1 activity. Although the treatments were anticipated to have secondary,
unintended side-effects, the concept was that by using more than one treatment condition
directed at each pyridine nucleotide redox pair, the combined data would reveal a preference
of intact pulmonary endothelial cell NQO1 for endogenous NADH or NADPH.
The pyridine nucleotide measurements were of total cell KOH-extractable cellular pyridine
nucleotides, with no distinction between protein-bound and free forms or information regarding
intracellular compartmentation (e.g., cytosolic or mitochondrial). The supposition was that
insofar as the treatment conditions were directed at glycolysis and the pentose phosphate
pathway, or included lactate, the cytosolic compartment was a key contributor to the observed
changes in total cell oxidized/reduced pyridine nucleotide ratios.
The common effects of the treatment conditions on the NADPH/NADP+ ratios and the
reduction rates of the NQO1 electron acceptor, DQ, suggest NADPH as the endogenous
electron donor for NQO1. The evidence consists of the observations that the pentose phosphate
pathway inhibitor, EPI, decreased NQO1 activity and that when DQ was also present, the
NADPH/NADP+ but not the NADH/NAD+ ratios were depressed. The absence of an effect of
the glycolytic inhibitor, IOA, on NQO1 activity and the NADPH/NADP+ ratios provided
indirect support for NADPH as the endogenous NQO1 electron donor, as did the observation
that lactate did not overcome the inhibitory effect of 2-DG on NQO1 activity.
The inhibitor sensitivity profile for TPMET was markedly distinct from that of NQO1. The
insensitivity of TPMET to pentose phosphate pathway blockade, the sensitivity to glycolytic
inhibitors, the responsiveness to lactate, and the overall relationship between NADH/NAD+
redox status and TPMET activity were in sharp contrast with NQO1. These observations
strongly suggested NADH rather than NADPH as the cytosolic TPMET electron donor,
confirming our previous observations [25].
The 2-DG treatment was carried out in the absence of glucose, a combination that might be
expected to decrease glycolytic flux and pentose phosphate pathway activity due to G-6-P
depletion and also inhibit glycolysis via 2-DG inhibition of phosphohexose isomerase and
hexokinase [28]. An additional mechanism to depress pentose phosphate activity is suggested
by the Figure 5 study showing that 2-DG-6-P is not as good a substrate as the physiological
G-6-P (Control) in a cytosol fraction G-6-PDH assay, consistent with observations in other
studies [29,30]. Whereas distinguishing the relative contributions of these mechanisms to the
observed effects was outside the scope of the present study, the key point is that 2-DG inhibition
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of both NQO1 and TPMET activities is consistent with the decreased capacity to regenerate
both NADH via glycolysis and NADPH via the pentose phosphate pathway.
IOA was used to target glycolysis via inhibition of glyceraldehyde-3-phosphate dehydrogenase
[31]. Accordingly, there was a dramatic decrease in the NADH/NAD+ ratio and TPMET
activity, both of which were overcome with lactate, consistent with previous observations
[25]. However, IOA had no detectable effect on NQO1 activity, suggesting that a decrease in
the glycolytic supply of NADH was not a limiting factor for DQ reduction via NQO1.
Both 2-DG and IOA decreased the total NAD+ + NADH and NADP+ + NADPH concentrations
in the cells, revealing a compromised ability to maintain normal pyridine nucleotide levels.
One explanation is depletion of the total pyridine nucleotide pool via activation of protective
mechanisms including, e.g., NAD+ dependent poly(ADP-ribose) polymerase-1 (PARP-1),
sirtuins or other pathways [32,33]. Regardless of the mechanisms involved, there was no
detectable effect on cell viability, total cell protein or total cell LDH activity (see Methods
Section) over the experimental time course.
EPI is a G-6-PDH inhibitor that has been used to evaluate the contribution of pentose phosphate
pathway derived NADPH to various processes, including hypoxic pulmonary vasoconstrictor
responses [34,35]. The observation that EPI inhibited NQO1 activity is thus consistent with a
role of pentose phosphate derived NADPH in NQO1 mediated DQ reduction in the cells.
However, an impact of EPI on the NADPH/NADP+ ratio was only revealed when DQ was also
present. This might be explained by noting again that the pyridine nucleotide measurements
were of total KOH extractable pyridine nucleotides, and therefore do not give information
regarding distribution in intracellular compartments [36–38]. Thus, the apparent maintenance
of a normal NADPH/NADP+ ratio in the presence of EPI may reflect domination of the
measured total cell NADPH/NADP+ ratio by a cellular compartment that depends on, e.g.,
NADP+-isocitrate dehydrogenase, malate dehydrogenase and/or nicotinamide nucleotide
transhydrogenase for regeneration of NADPH. Alternatively, it may be that under resting
conditions, there is little drain on the NADPH pool, and that blockade of the pentose phosphate
pathway has no appreciable impact on resting NADPH/NADP+ because there is no need to
replenish NADPH when NQO1 is not activated by DQ. This would be analogous to
observations in bovine coronary arteries in which glucose deprivation alone does not alter
cytosolic NADPH levels, but a hypoxia-induced depression in cytosolic NADPH was
exacerbated in glucose-free medium [39].
An alternative or additional explanation for the DQ or DQ + EPI induced decline in the
NADPH/NADP+ ratio is NADPH depletion via one-electron DQ reduction and subsequent
redox cycling. However, our previous studies suggest that redox cycling is not a predominant
pathway of DQ metabolism in pulmonary endothelial cells under these or very similar reaction
conditions we have studied. First, as compared to the classical redox cycling quinone,
menadione, there was little detectable DQ mediated superoxide generation from these cells,
measured as a BMPO-radical adduct signal by electron paramagnetic resonance spectroscopy
[30]. This was consistent with observations of other investigators that DQ did not elicit
appreciable reactive oxygen species formation from rat hepatocytes or PC12 cells in a series
of other, more reactive benzoquinones [40]. Secondly, at the same DQ concentrations used in
the present study (50 μM) nearly all the DQ reduction mediated by the pulmonary endothelial
cells was blocked with NQO1 inhibitors and, in the absence of NQO1 inhibitors, all the DQ
added to the cells could be accounted for as either DQ or DQH2 at the end of a 30 minute
incubation [30]. Furthermore, DQH2 is a relatively stable hydroquinone with a low propensity
to autooxidize over the experimental time frame [30].
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The results of the present study taken together with the aforementioned observations strongly
suggest that the vast majority of DQ metabolism in pulmonary endothelial cells is attributable
to NQO1 driven reduction to DQH2, and that NQO1 utilization of NADPH provides a
reasonable explanation for DQ mediated NADPH depletion. One implication is that the
capacity to supply NADPH at a sufficient rate to maintain optimal NQO1 activity under
oxidative stress or other conditions constituting an additional drain on NAD(P)H may limit the
therapeutic utility of NQO1 as a target for activation of blood borne chemotherapeutic and
antioxidant compounds [16,41–43].
It is perhaps not surprising that NADPH would be the endogenous electron donor for NQO1
even though isolated NQO1 has little intrinsic preference for it over NADH. The majority of
the reducing power for phase II and antioxidant enzymes is attributable to NADPH, and total
cell NADPH levels in the pulmonary endothelial cells, as well as in liver, are 2–3 times higher
than total NADH [36,38,44]. This discrepancy is even greater when considering the cytosolic
compartment, where NADPH concentrations are estimated to be orders of magnitude greater
than NADH, and where protein binding further depletes the NADH pool [36,38,44–46].
Finally, although studies of the isolated enzyme show that the Vmax for NQO1 is about the
same regardless of whether NADH or NADPH is the electron donor, the Km for NADPH is
about one-half that of NADH [1]. Taken together, the weight of the evidence suggests that
NADH would be unlikely to be present in a high enough concentration in the cytosol to compete
with NADPH for NQO1. However, a key point of this study is that despite the very low relative
abundance of NADH as compared to NADPH in the cytosolic compartment, the capacity to
supply NADH is sufficient to maintain TPMET activity at a rate comparable to NADPH
supported NQO1 mediated DQ reduction.
In their initial studies of NQO1, Ernster et. al proposed it as the predominant NADPH oxidizing
enzyme in the liver cell cytosol, and hypothesized a role in regulating oxidation of cytosolic
reduced pyridine nucleotides [3]. At that time, it was considered that NQO1 might participate
in providing reducing equivalents to the mitochondrial electron transport chain [47]. This
concept formed the basis for the therapeutic utility of quinones in treatment of defects in
mitochondrial respiration, and recent observations in NQO1 knockout mice are consistent with
the prediction that NQO1 participates in maintenance of pyridine nucleotide redox status
[14,43].
In conclusion, the present study demonstrates that cytoplasmic redox status, as reflected in the
NADH/NAD+ and NADPH/NADP+ ratios, affects TPMET reduction of thiazine compounds
and NQO1 mediated quinone reduction. The results also provide confirmation of previous
observations that TPMET activity reflects the NADH/NAD+ ratio, and suggest, that in contrast
to TPMET, NQO1 activity is more closely tied to the NADPH/NADP+ ratio. In addition, future
studies may be warranted to evaluate TBOP+ and DQ reduction as nondestructive indices of
changes in cell redox status.
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Figure 1. Experimental approach for measuring intact cell (A) NQO1 and (C) TPMET activity
The ferricyanide concentrations in the extracellular medium vs time for example experiments.
(A) For the Without DQ conditions (open symbols), the extracellular medium contained
ferricyanide alone (control) or ferricyanide and dicumarol or ES936. For the With DQ
conditions (closed symbols), the extracellular medium contained ferricyanide with DQ
(control) or with DQ and dicumarol or ES936. (B) For the Without TBOP conditions (open
symbols) the extracellular medium contained ferricyanide alone (control) or ferricyanide with
dicumarol. For the With TBOP conditions (closed symbols) the extracellular medium
contained ferricyanide with TBOP (control) or with TBOP with dicumarol. The number of
experiments (n) carried out for each condition were as follows: (A) without DQ, control (3),
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dicumarol (3), ES936 (3); with DQ, control (26), dicumarol (8), ES936 (4); (B) without TBOP,
control (3), dicumarol (3); with TBOP, control (21), dicumarol (6). The cell protein (mean ±
SEM) in (A) was 1.57 ± 0.06 mg per sample and in (B) was 1.68 ± 0.07 mg per sample, and
there were no significant differences between the protein concentrations within the (A) studies
or within the (C) studies. *Significantly different from control (p<0.05), Kruskal-Wallis one-
way ANOVA on ranks and Dunn’s test.
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Figure 2. Effects of inhibitors of glycolysis and pentose phosphate pathway on NQO1 (A) and
TPMET (B) activities
The activities were calculated from the ferricyanide concentration versus time curves
(exemplified in Figure 1) in the presence of DQ to measure NQO1 activity (A) or in the presence
of TBOP+ to measure TPMET activity (B), in the absence (control) and presence of the
inhibitors. The number of experiments (n) carried out for each condition were as follows: (A)
control (26), 2-DG (10), IOA (17), EPI (10); (B) control (21), 2-DG (10), IOA (11), EPI (11).
*Significantly different from control (p<0.05), Kruskal-Wallis one-way ANOVA on ranks and
Dunn’s test.
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Figure 3.
Effects of inhibitors of glycolysis and pentose phosphate pathway on intracellular NADPH/
NADP+ (A) and NADH/NAD+ (B). The number of experiments (n) carried out were as follows:
control (61), 2-DG (11), IOA (12), EPI (23), DQ (9), DQ + EPI (7). *Significantly different
from control (p<0.05), Kruskal-Wallis one-way ANOVA on ranks and Dunn’s test.
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Figure 4. Lactate restores NADH/NAD+ ratios (A) and TPMET activity (B) in the presence of 2-
DG or IOA
(A) The NADH/NAD+ ratios were calculated from the values shown in Table 1. (B) The
number of experiments (n) carried were as follows: control, − lactate (21), + lactate (6); 2-DG,
− lactate (10), + lactate (4); IOA, − lactate (11), + lactate (5). *Significantly different from
control (p<0.05); † significantly different from paired treatment without lactate (− lactate),
(p<0.05), Kruskal-Wallis one-way ANOVA on ranks and Dunn’s test.
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Figure 5. Lactate does not affect NADPH/NADP+ ratios (A) or NQO1 activity (B) in the presence
of 2-DG or EPI
(A) The NADPH/NADP+ ratios were calculated from the values shown in Table 1. (B) The
number of experiments (n) carried out were as follows: control, − lactate (26), + lactate (11);
2-DG, − lactate (10), + lactate (4); EPI, − lactate (10), + lactate (4). *Significantly different
from controls (p<0.05), Kruskal-Wallis one-way ANOVA on ranks and Dunn’s test.
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Figure 6. EPI does not inhibit NQO1 activity directly, but does inhibit G-6-PDH activity in cell
cytosol fractions
The numbers of experiments (n) carried out in were as follows: (A) control (4), EPI (4); (B)
control (10), EPI (6), 2-DG-6-P (6), 2-DG-6-P + EPI (5). *Significantly different from control;
†significantly different from EPI; ‡ significantly different from 2-DG-6P, p<0.05, one way
ANOVA and Tukey test.
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